LifeArc portfolio company RQ Bio’s antibody enters clinical trials
LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
LifeArc’s Head of Ventures, Clare Terlouw speaks with @FT Global Pharma Correspondent @hannahkuchler discussing RQ… https://t.co/fqrxEXr3Xf
Alzheimer’s drug lecanemab approved by US regulator
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.
Evolving our science to solve complex healthcare challenges
Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.
2022 wrapped – our highlights from a pivotal year
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
MND Collaborative Partnership cautiously welcomes new Government funding
We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.
Repurposed flu medicine could help under 60s recover faster from COVID-19
Results of an international repurposing study show favipiravir could help with COVID-19.
LifeArc bolsters executive team with communications expertise
Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer.
LifeArc announces £10m funding call for new chronic respiratory infection therapies
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge